Stephan Probst

List of Publications by Year
in descending order

50 papers	775 citations	687220 13 h-index	552653 26 g-index
50 all docs	50 docs citations	50 times ranked	1250 citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ^{18}F-DCFPyL in Prostate Cancer Patients (OSPREY). Journal of Urology, 2021, 206, 52-61.	0.2	180
2	Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: A prospective study. Gynecologic Oncology, 2012, 127, 332-337.	0.6	77
3	Predicting Gleason Score of Prostate Cancer Patients Using Radiomic Analysis. Frontiers in Oncology, 2018, 8, 630.	1.3	72
4	Inferior parietal transcranial direct current stimulation with training improves cognition in anomic Alzheimer's disease and frontotemporal dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 247-253.	1.8	70
5	Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer. Canadian Association of Radiologists Journal, 2021, 72, 109-119.	1.1	51
6	Impact of sentinel lymph node mapping on recurrence patterns in endometrial cancer. Gynecologic Oncology, 2017, 144, 503-509.	0.6	41
7	Unexpected locations of sentinel lymph nodes in endometrial cancer. Gynecologic Oncology, 2017, 147, 18-23.	0.6	33
8	18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications. Nuclear Medicine Communications, 2019, 40, 377-382.	0.5	27
9	Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1041-1051.	3.3	22
10	Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review. Cancers, 2021, 13, 552.	1.7	21
11	Atypical Bisphosphonate-Associated Subtrochanteric and Femoral Shaft Stress Fractures. Clinical Nuclear Medicine, 2013, 38, 397-399.	0.7	20
12	Extraosseous Extension of Aggressive Vertebral Hemangioma as a Potential Pitfall on 68Ga-PSMA PET/CT. Clinical Nuclear Medicine, 2017, 42, 624-625.	0.7	19
13	Systemic Lupus Erythematosus Associated Pitfalls on 18F-FDG PET/CT: Reactive Follicular Hyperplasia, Kikuchi-Fujimoto Disease, Inflammation and Lymphoid Hyperplasia of the Spleen Mimicking Lymphoma. Nuclear Medicine and Molecular Imaging, 2018, 52, 74-79.	0.6	18
14	Maximizing the Treatment Benefit of tDCS in Neurodegenerative Anomia. Frontiers in Neuroscience, 2019, 13, 1231.	1.4	11
15	Blinded Clinical Evaluation for Dementia of Alzheimer's Type Classification Using FDG-PET: A Comparison Between Feature-Engineered and Non-Feature-Engineered Machine Learning Methods. Journal of Alzheimer's Disease, 2021, 80, 715-726.	1.2	11
16	A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.. Journal of Clinical Oncology, 2020, 38, 9-9.	0.8	10
17	Initial single-centre Canadian experience with 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/ CT) for biochemical recurrence in prostate cancer patients initially treated with curative intent. Canadian Urological Association Journal, 2017, 11, 47.	0.3	9
18	Sarcopenia in cardiac surgery: Dual X-ray absorptiometry study from the McGill frailty registry. American Heart Journal, 2021, 239, 52-58.	1.2	8

#	Article	IF	Citations
19	Disseminated Multi-system Sarcoidosis Mimicking Metastases on 18F-FDG PET/CT. Molecular Imaging and Radionuclide Therapy, 2018, 27, 91-95.	0.3	8
20	Erdheim-Chester Disease: The Importance of Information Integration. Case Reports in Oncology, 2017, 10, 613-619.	0.3	7
21	Composite Cutaneous Lymphoma (Iatrogenic Immunodeficiency-Associated Lymphoproliferative) Tj ETQq1 1 0.784314 rgBT /Overloc of Response to Therapy with 18F-FDG PET/CT. Nuclear Medicine and Molecular Imaging, 2017, 51, 261-265.	0.6	6
22	The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. BJU International, 2022, 130, 314-322.	1.3	6
23	18F-fluorocholine positron emission tomography-computed tomography (18F-FCH PET/CT) for staging of high-risk prostate cancer patients. Canadian Urological Association Journal, 2018, 13, 84-91.	0.3	4
24	Diagnostic performance of 18F-DCFPyL positron emission tomography/computed tomography for biochemically recurrent prostate cancer and change-of-management analysis. Canadian Urological Association Journal, 2020, 15, 173-178.	0.3	4
25	Ureteral Metastasis From Prostate Cancer. Clinical Nuclear Medicine, 2020, 45, 689-691.	0.7	4
26	A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).. Journal of Clinical Oncology, 2018, 36, TPS5092-TPS5092.	0.8	4
27	I-131 Radiation-Induced Myelosuppression in Differentiated Thyroid Cancer Therapy. Molecular Imaging and Radionuclide Therapy, 2018, 27, 84-87.	0.3	3
28	The semantic storage loss score: An Algorithm for measuring an individual's level of semantic storage loss due to temporal lobe damage in neurodegenerative disease. PLoS ONE, 2020, 15, e0235810.	1.1	3
29	Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study. Frontiers in Oncology, 2020, 10, 312.	1.3	3
30	Physiologic prostate-specific membrane antigen-targeted 18F-DCFPyL uptake in the epididymis head newly appreciated on digital PET/CT. Nuclear Medicine Communications, 2021, 42, 490-494.	0.5	3
31	Appearance of CNS histoplasmosis on 18F-FDG PET/CT with MRI correlation. BJR|case Reports, 2016, 2, 20150443.	0.1	2
32	Follicular lymphoma transforming into diffuse large B-cell lymphoma in spleen: Simultaneous appearance of both on 18 F-FDG PET/CT and histology. Clinical Imaging, 2017, 43, 88-92.	0.8	2
33	A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).. Journal of Clinical Oncology, 2021, 39, TPS187-TPS187.	0.8	2
34	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. Journal of Clinical Oncology, 2021, 39, 32-32.	0.8	2
35	Reply by Authors. Journal of Urology, 2021, 206, 61-61.	0.2	2
36	A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).. Journal of Clinical Oncology, 2020, 38, TPS5596-TPS5596.	0.8	2

#	Article	IF	Citations
37	Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer. Nuclear Medicine and Molecular Imaging, 2022, 56, 188-195.	0.6	2
38	Extensive polyostotic fibrous dysplasia evaluated for malignant transformation with^{99m}Tc-MDP bone scan and^{18}F-FDG PET/CT. BJR|case Reports, 2016, 2, 20150440.	0.1	1
39	Weight loss as primary indication for FDG-PET/CT. Nuclear Medicine Communications, 2020, 41, 1066-1072.	0.5	1
40	Inflammatory and Ischemic Post Liver Transplant Complications Mimic Malignancy on 18F-FDG PET/CT. Molecular Imaging and Radionuclide Therapy, 2018, 27, 37-40.	0.3	1
41	Primary Thyroid Lymphoma: External Beam Radiation Therapy Induced Thyroiditis Mimics Residual Disease on Serial 18F-FDG PET/CT Imaging. Molecular Imaging and Radionuclide Therapy, 2018, 27, 41-47.	0.3	1
42	A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).. Journal of Clinical Oncology, 2020, 38, TPS260-TPS260.	0.8	1
43	Piflufolastat F 18-PET/CT in patients with prostate cancer: An analysis of OSPREY (cohorts A and B) standardized uptake value (SUV) results stratified by PSA and Gleason score.. Journal of Clinical Oncology, 2022, 40, 5024-5024.	0.8	1
44	Colonic manifestation of a haematologic disorder. Arab Journal of Gastroenterology, 2016, 17, 191-192.	0.4	0
45	A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. Journal of Clinical Oncology, 2021, 39, e17003-e17003.	0.8	0
46	18F-fluorodeoxyglucose positron emission tomography/computed tomography in extensive bland portal vein thrombosis from retroperitoneal adenocarcinoma. World Journal of Nuclear Medicine, 2019, 18, 192.	0.3	0
47	Incidental Hydroxyapatite Ocular Implant Uptake on Bone Scan Done for Prostate Cancer Staging: Case Report and Brief Review. Molecular Imaging and Radionuclide Therapy, 2019, 28, 86-88.	0.3	0
48	Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. European Urology, 2022, 81, 437-439.	0.9	0
49	Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.. Journal of Clinical Oncology, 2022, 40, 35-35.	0.8	0
50	Immune profiling of a patient with relapsed HIV-Related and EBV-positive diffuse large B-Cell lymphoma treated with pembrolizumab. Leukemia and Lymphoma, 2021, , 1-5.	0.6	0